收藏切换
Application of bictegravir/emtricitabine/tenofovir alafenamide in rapid initiation of antiretroviral therapy: a review
收藏切换
Rentian CAI1, Fang ZHENG1, 2, Hongxia WEI1
Chinese Journal of Public Health | 2026, 42(6) : 755 - 761
Less
收藏切换
Chinese Journal of Public Health | 2026, 42(6): 755-761
• Review •
Application of bictegravir/emtricitabine/tenofovir alafenamide in rapid initiation of antiretroviral therapy: a review
Full
Rentian CAI1, Fang ZHENG1, 2, Hongxia WEI1
Affiliations
  • 1Department of Infection, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine (The Second Hospital of Nanjing), Nanjing 211100, China
  • 2Department of Infection and Immunology, Changsha Hospital Affiliated to Xiangya Hospital, Central South University, Changsha 410005, China
Published: 2026-06-10 doi: 10.11847/zgggws1146535
Outline
收藏切换

Rapid initiation of antiretroviral therapy (rapid ART) has multiple clinical benefits, such as increasing the rates of treatment initiation, retention in care, and virologic suppression, and reducing the mortality rate. It is crucial for the achievement of the “95%–95%–95%” goal in China and the globe. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet combination based on the second-generation integrase inhibitor bictegravir. B/F/TAF has a high resistance barrier and a favourable safety profile, and can be initiated before baseline laboratory results are available. It is not only a first-line ART regimen recommended by the latest established guidelines but also the only single-tablet regimen unanimously recommended by local and international guidelines for rapid ART. A number of prospective clinical trials and cohort studies on the use of B/F/TAF for rapid ART are currently ongoing in China and across the world, including studies using same-day initiation. This article summarizes the existing clinical evidence and briefly discusses the considerations for the use of B/F/TAF for rapid ART in some special populations, aiming to inform the clinical practice of medical personnel engaged in the diagnosis and treatment of HIV infection.

B/F/TAF  /  rapid initiation of antiretroviral therapy  /  same-day initiation  /  AIDS prevention and treatment  /  virologic suppression
蔡仁田, 郑芳, 魏洪霞. 比克替拉韦/恩曲他滨/丙酚替诺福韦(B/F/TAF)在快速启动抗反转录病毒治疗中的应用. 中国公共卫生, 2026 , 42 (6) : 755 -761 . DOI: 10.11847/zgggws1146535
Rentian CAI, Fang ZHENG, Hongxia WEI. Application of bictegravir/emtricitabine/tenofovir alafenamide in rapid initiation of antiretroviral therapy: a review[J]. Chinese Journal of Public Health, 2026 , 42 (6) : 755 -761 . DOI: 10.11847/zgggws1146535
Year 2026 volume 42 Issue 6
83
33
Cite this Article
BibTeX
Article Info
doi: 10.11847/zgggws1146535
  • Receive Date:2024-11-28
  • Online Date:2026-10-23
  • Published:2026-06-10
Article Data
Affiliations
History
  • Received:2024-11-28
  • Revised:2025-02-17
  • Accepted:2025-08-06
Affiliations
    1Department of Infection, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine (The Second Hospital of Nanjing), Nanjing 211100, China
    2Department of Infection and Immunology, Changsha Hospital Affiliated to Xiangya Hospital, Central South University, Changsha 410005, China

Corresponding:

WEI Hongxia, E-mail:
References
Share
https://castjournals.cast.org.cn/joweb/zgggws/EN/10.11847/zgggws1146535
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT